Provided by Tiger Trade Technology Pte. Ltd.

Insmed

149.86
-1.1700-0.77%
Post-market: 148.97-0.8900-0.59%19:59 EST
Volume:2.63M
Turnover:398.33M
Market Cap:31.68B
PE:-24.10
High:155.79
Open:153.06
Low:149.34
Close:151.03
52wk High:212.75
52wk Low:60.40
Shares:211.37M
Float Shares:194.00M
Volume Ratio:1.15
T/O Rate:1.36%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-6.2193
EPS(LYR):-5.5703
ROE:-165.69%
ROA:-28.05%
PB:33.50
PE(LYR):-26.90

Loading ...

Insmed Chief Medical Officer Martina Flammer Reports Disposal of Common Shares

Reuters
·
Feb 07

Analysts Offer Insights on Healthcare Companies: Insmed (INSM), Oncolytics Biotech (ONCY) and Imunon (IMNN)

TIPRANKS
·
Feb 06

Insmed (INSM) Executives Engage in Coordinated Stock Sale

TIPRANKS
·
Feb 06

Insmed Inc. to Announce Fourth-Quarter and Full-Year Financial Results

Reuters
·
Feb 05

Insmed CEO William Lewis Reports Disposal of Common Shares

Reuters
·
Feb 05

Insmed’s ENCORE Trial Reaches Key Milestone in MAC Lung Infection

TIPRANKS
·
Feb 04

BUZZ - Nasdaq top and bottom performing stocks at about 11:01 a.m. EST on 2026-02-02

Reuters
·
Feb 03

The Druckenmiller Connection: Meet the Man Behind Bessent and Warsh -- Barrons.com

Dow Jones
·
Feb 02

Insmed call volume above normal and directionally bullish

TIPRANKS
·
Jan 31

Insmed Is Maintained at Equal-Weight by Morgan Stanley

Dow Jones
·
Jan 31

Morgan Stanley Sticks to Its Hold Rating for Insmed (INSM)

TIPRANKS
·
Jan 30

Definium Therapeutics appoints Roger Adsett to board of directors

TIPRANKS
·
Jan 29

Insmed Initiated at Overweight by Barclays

Dow Jones
·
Jan 28

Barclays Initiates Coverage on Insmed With Overweight Rating, $231 Price Target

MT Newswires Live
·
Jan 28

Insmed Unveils Phase 3 TPIP Study Design for Pulmonary Arterial Hypertension at PVRI 2026

Reuters
·
Jan 28

Analysts Are Bullish on Top Healthcare Stocks: Insmed (INSM), Sanara MedTech (SMTI)

TIPRANKS
·
Jan 27

BUZZ - Nasdaq top and bottom performing stocks at about 11:01 a.m. EST on 2026-01-23

Reuters
·
Jan 24

Insmed Initiated at Buy by Roth Capital

Dow Jones
·
Jan 23

Roth Capital Initiates Coverage on Insmed With Buy Rating, $212 Price Target

MT Newswires Live
·
Jan 23

Insmed initiated with a Buy at Roth Capital

TIPRANKS
·
Jan 23